The efficacy of omega-3 supplementation for major depression: A randomized controlled trial

Journal of Clinical Psychiatry

Volumn 72, Issue 8, 2011, Pages 1054-1062

  Lespérance, François ^a,b,c   Frasure Smith, Nancy ^a,b,c,d   St André, Elise ^a   Turecki, Gustavo ^c,e   Lespérance, Paul ^a,b   Wisniewski, Stephen R ^f  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; SUNFLOWER OIL;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BLOATING; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DECUBITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; HEADACHE; HEART INFARCTION; HEARTBURN; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MYALGIA; NAUSEA; NEUROPATHIC PAIN; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SORE THROAT; SUPPLEMENTATION; SYMPTOMATOLOGY; TASTE DISORDER; THROMBOPHLEBITIS;

ADULT; ANXIETY DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; HUMANS; MALE; MIDDLE AGED; PLANT OILS;

EID: 80052433479     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m05966blu     Document Type: Article

References (53)

1. Rush AJ. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry. 2007;68(suppl 10):8-10. PubMed
2. MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003;326(7397):1014-1019. doi:10.136/bmj.326.7397.1014 PubMed
3. Simon GE, VonKorff M, Wagner EH, et al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry. 1993;15(6):399-408. doi:10.1016/0163-8343(93)909-D PubMed
4. Kessler RC, Soukup J, Davis RB, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry. 2001;158(2):289-294. doi:10.176/api.ajp.158.2.289 PubMed
5. Parker G, Gibson NA, Brotchie H, et al. Omega-3 fatty acids and mood disorders. Am J Psychiatry. 2006;163(6):969-978. doi:10.176/api.ajp.163.6.969 PubMed
6. Appleton KM, Rogers PJ, Ness AR. Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? a review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutr Res Rev. 2008;21(1):13-41. doi:10.1017/S0954240898620 PubMed
7. Maes M, Yirmyia R, Noraberg J, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24(1): 27-53. doi:10.107/s101-08-918-1 PubMed
8. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids. 2006;75(4-5):259-269. doi:10.1016/j.plefa.206.07.05 PubMed
9. Appleton KM, Hayward RC, Gunnell D, et al. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr. 2006;84(6):1308-1316. PubMed
10. Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis. 2007;6(1):21-39. doi:10.186/1476-51X-6-21 PubMed
11. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68(7):1056-1061. doi:10.408/JCP.v68n0712 PubMed
12. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67(12):1954-1967. doi:10.408/JCP.v67n1217 PubMed
13. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyleicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002;59(10):913-919. doi:10.101/archpsyc.59.10.913 PubMed
14. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159(3):477-479. doi:10.176/api.ajp.159.3.47 PubMed
15. Su KP, Huang SY, Chiu CC, et al. Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13(4):267-271. doi:10.1016/S0924-97X(03)032-4 PubMed
16. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260. doi:10.1056/NEJMsa06579 PubMed
17. Mischoulon D, Papakostas GI, Dording CM, et al. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry. 2009;70(12):1636-1644. doi:10.408/JCP.08m04603 PubMed
18. Silvers KM, Woolley CC, Hamilton FC, et al. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids. 2005;72(3):211-218. doi:10.1016/j.plefa.204.1.04 PubMed
19. Grenyer BF, Crowe T, Meyer B, et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(7):1393-1396. doi:10.1016/j.pnpbp.207.06.04 PubMed
20. Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry. 2003;160(5):996-998. doi:10.176/api.ajp.160.5.96 PubMed
21. Zimmerman M, Chelminski I, Posternak MA. Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included. J Nerv Ment Dis. 2004;192(2):87-94. doi:10.1097/01.nmd.010279.23893.82 PubMed
22. Hibbeln JR, Makino KK, Martin CE, et al. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol Psychiatry. 2003; 53(5):431-441. doi:10.1016/S06-323(02)01549-4 PubMed
23. Hibbeln JR. Fish consumption and major depression. Lancet. 1998; 351(9110):1213. doi:10.1016/S0140-6736(05)79168-6 PubMed
24. Lecrubier Y, Sheehan DV, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 1997;12(5):224-231. doi:10.1016/S0924-938(97)83296-8
25. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73-82. doi:10.1017/ S032917030107 PubMed
26. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4. 382 PubMed
27. Stoll AL, Damico KE, Daly BP, et al. Methodological considerations in clinical studies of omega 3 fatty acids in major depression and bipolar disorder. World Rev Nutr Diet. 2001;88:58-67. doi:10.159/059745 PubMed
28. Rees JR, Wade TJ, Levy DA, et al. Changes in beliefs identify unblinding in randomized controlled trials: a method to meet CONSORT guidelines. Contemp Clin Trials. 2005;26(1):25-37. doi:10.1016/j.ct.204.1.020 PubMed
29. Rush AJ, Trivedi MH, Carmody TJ, et al. Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. Neuropsychopharmacology. 2005;30(2):405-416. doi:10.1038/sj.np.130614 PubMed
30. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am. 2003;26(2):457-494, x. doi:10.1016/S0193-953X(02)0107-7 PubMed
31. Carmody TJ, Rush AJ, Bernstein I, et al. The Montgomery Åsberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol. 2006;16(8):601-611. doi:10.1016/j.euroneuro.206.04.08 PubMed
32. US Department of Health and Human Services. Code of Federal Regulations Title 21. US Food and Drug Administration Web site. http://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32. Revised April 1, 2009.
33. Wisniewski SR, Rush AJ, Balasubramani GK, et al. STAR*D Investigators. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12(2):71-79. doi:10.1097/0131746- 206030-02 PubMed
34. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002; 287(14):1840-1847. doi:10.101/jama.287.14.1840 PubMed
35. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42(3):507-519. doi:10.2307/2531201 PubMed
36. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry. 2007;164(8):1189-1197. doi:10.176/api.ajp.207.0607125 PubMed
37. Stewart JW, McGrath PJ, Fava M, et al. Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol. 2010;13(1):15-30. doi:10.1017/S1461457090182 PubMed
38. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? a STAR*D report. Am J Psychiatry. 2009;166(5):599-607. doi:10.176/api.ajp. 208.08071027 PubMed
39. Khan A, Kolts RL, Thase ME, et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry. 2004;161(11):2045-2049. doi:10.176/api.ajp.161.1.2045 PubMed
40. Hennekens CH, Demets D. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. JAMA. 2009;302(21):2361-2362. doi:10.101/jama.209.1756 PubMed
41. Howland RH, Rush AJ, Wisniewski SR, et al. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend. 2009;99(1-3):248-260. doi:10.1016/j.drugalcdep.208.08.010 PubMed
42. aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009;180(3):305-313. PubMed
43. Gordon JA, Hen R. The serotonergic system and anxiety. Neuromolecular Med. 2004;5(1):27-40. doi:10.1385/NM:5:1:027 PubMed
44. Papakostas GI, Stahl SM, Krishen A, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008;69(8):1287-1292. doi:10.408/JCP.v69n0812 PubMed
45. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56. doi:10.1038/nrn297 PubMed
46. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21(6):495-505. PubMed
47. Carney RM, Freedland KE, Rubin EH, et al. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA. 2009;302(15):1651-1657. doi:10.101/jama.209. 1487 PubMed
48. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: III pharmacotherapy. J Affect Disord. 2009;117(suppl 1):S26-S43. doi:10.1016/j.jad.209.06.041 PubMed
49. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev. 2004;(1):CD003012. PubMed
50. Höschl C. European perspectives in psychiatry: antidepressants as an example. Acta Psychiatr Scand. 2008;118(2):89-90. doi:10.1/j.160-047.208.01218. x PubMed
51. Mathew SJ, Charney DS. Publication bias and the efficacy of antidepressants. Am J Psychiatry. 2009;166(2):140-145. doi:10.176/api.ajp.208. 0807102 PubMed
52. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. http://www.nice.org.uk/cg023. Accessed August 3, 2009.
53. Saremi A, Arora R. The utility of omega-3 fatty acids in cardiovascular disease. Am J Ther. 2009;16(5):421-436. doi:10.1097/MJT.0b013e3180a5f0b PubMed